Integra Lifesciences ((IART)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Integra LifeSciences is conducting an observational cohort analysis titled ‘An Observational Cohort Analysis of Tissue Quality of Integra Dermal Matrix (Integra®)-Treated Burns and NovoSorb® Biodegradable Temporizing Matrix (BTM)-Treated Burns 12-36 Months Post Final Skin Graft Application.’ The study aims to evaluate the tissue quality of burns treated with Integra and BTM, providing insights into their long-term effectiveness and patient outcomes.
Intervention/Treatment: The study examines two interventions: the Integra Dermal Matrix and the NovoSorb Biodegradable Temporizing Matrix (BTM). Both are used in conjunction with standard care to treat burn injuries, aiming to improve tissue quality and healing outcomes.
Study Design: This observational study employs a cohort model, focusing on patients treated with Integra, BTM, or a combination of both. It will analyze medical records and use non-invasive measures to assess tissue quality, with optional biopsies for further evaluation.
Study Timeline: The study is not yet recruiting, with an initial submission date of November 19, 2024, and the latest update on May 5, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.
Market Implications: This study could significantly impact Integra LifeSciences’ stock performance by providing evidence of the effectiveness of their products. Positive results may enhance investor confidence and position Integra favorably against competitors in the burn treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.